glp 1 agonist brand names india Eli Lilly could launch obesity drug in next year, CEO says 2025’s Breakthrough GLP-1 Obesity Treatments:
Description
Filippatos TD, Panagiotopoulou TV, Elisaf MS
doi: 10.1038/s41598-017-09898-4
Riddy, D
doi: 10.1053/j.gastro.2004.04.063 27 SmitsMMTonneijckLMuskietMHAKramerMHHCahenDLvan RaalteDH
Patients with type 2 diabetes, especially those with cardiovascular disease, chronic kidney disease, obesity, or NAFLD, may benefit from GLP-1 receptor agonists as part of their treatment regimen
Post hoc evaluations of the SUSTAIN 6 trial revealed that semaglutide markedly increased the incidence of diabetic retinopathy complications in individuals with a history of retinopathy, especially among insulin users, presumably due to the swift deterioration of pre-existing retinopathy following rapid glycemic control [91]
